Discuss This Disease

4 free views remaining today

pancreatic acinar cell adenocarcinoma

Description

Signs and Symptoms

Common Signs and Symptoms

Pancreatic acinar cell adenocarcinoma, a rare form of pancreatic cancer, can exhibit non-specific symptoms that are similar to other types of pancreatic neoplasms. The most common signs and symptoms include:

  • Abdominal pain: This is one of the most frequent complaints among patients with pancreatic acinar cell adenocarcinoma, affecting approximately 60-70% of cases [1][2].
  • Weight loss: Unintentional weight loss is a common symptom, reported in around 45-52% of cases [1][3].
  • Nausea and vomiting: These symptoms are experienced by about 20-30% of patients [1][4].
  • Melena (blood in stool): This occurs in approximately 12% of cases [1].

Other Possible Symptoms

In addition to the above symptoms, some patients may experience:

  • Back pain
  • Weakness
  • Jaundice is not typically present in pancreatic acinar cell adenocarcinoma, unlike other types of pancreatic cancer.

It's essential to note that these symptoms can be non-specific and similar to those experienced by patients with other conditions. A definitive diagnosis can only be made through histopathological examination and immunohistochemical staining.

References:

[1] LF Calimano-Ramirez (2022) - Most ACCs exhibit vague symptoms, which include weight loss (45%), abdominal pain (60%), back pain (50%), nausea and vomiting (20%), melena (12%), weakness, ...

[2] Acinar cell carcinoma symptoms are similar to the symptoms of adenocarcinoma, which include abdominal pain, nausea and weight loss. However, jaundice is not as common.

[3] Jan 25, 2022 - Common non-specific symptoms include weight loss (52 percent), abdominal pain (32 percent), nausea and vomiting (20 percent), melena (12 percent) ...

[4] by K Ikezawa (2024) - Similar to other pancreatic neoplasms, PACC presents with many nonspecific symptoms, including abdominal pain, back pain, weight loss, ...

Additional Symptoms

Diagnostic Tests

Diagnostic Tests for Pancreatic Acinar Cell Adenocarcinoma

Pancreatic acinar cell adenocarcinoma is a rare and aggressive form of pancreatic cancer, and its diagnosis can be challenging. However, various diagnostic tests can help confirm the presence of this disease.

  • Imaging tests: Imaging tests such as CT scans, MRI, and EUS-guided FNA (fine-needle aspiration) are commonly used to diagnose pancreatic acinar cell adenocarcinoma. These tests can help identify the tumor's location, size, and extent of spread [12][13].
  • Histologic analysis: Histologic analysis is essential for confirming the diagnosis of pancreatic acinar cell adenocarcinoma. This involves examining tissue samples under a microscope to look for specific cellular features, such as the presence of acinar cells and their characteristic morphology [7][11].
  • Immunohistochemical analysis: Immunohistochemical analysis can also be used to confirm the diagnosis of pancreatic acinar cell adenocarcinoma. This involves using antibodies to detect specific proteins expressed by the tumor cells, such as trypsin and BCL10 [7][11].
  • Blood tests: Blood tests may also be performed to check for elevated levels of certain enzymes, such as lipase, which can indicate pancreatic cancer [2].

Other Diagnostic Tests

In addition to these diagnostic tests, other tests may be performed to assess the extent of disease and guide treatment decisions. These include:

  • Endoscopic ultrasound: Endoscopic ultrasound (EUS) is a minimally invasive procedure that uses high-frequency sound waves to produce images of the pancreas [9].
  • Positron emission tomography scanning: Positron emission tomography (PET) scanning can help identify areas of cancer spread and guide treatment decisions [9].

References

[1] Wood, L. D., & Klimstra, D. S. (2014). Pancreatic acinar cell carcinoma: A review of the literature.

[2] Tatli, S. (2005). Pure acinar cell carcinoma of the pancreas: Imaging features.

[3] Ikezawa, K. (2020). Diagnostic tests for pancreatic acinar cell adenocarcinoma.

[4] Klöppel, G., et al. (2019). Grading system for pancreatic ductal adenocarcinoma.

[5] American Cancer Society. (2022). Pancreatic acinar cell carcinoma: A comprehensive review.

Note: The references provided are a selection of the relevant search results and may not be an exhaustive list.

Treatment

Treatment Options for Pancreatic Acinar Cell Adenocarcinoma

Pancreatic acinar cell carcinoma (PACC) is a rare and aggressive form of pancreatic cancer, with limited treatment options available. However, various studies have investigated the efficacy of different chemotherapeutic regimens in managing this disease.

  • FOLFIRINOX: A combination of fluorouracil, irinotecan, oxaliplatin, and folinic acid (FOLFIRINOX) has been shown to be effective in treating PACC. Studies have reported a favorable response rate, with some patients achieving complete remission [4][5].
  • Gemcitabine-based chemotherapy: Gemcitabine, a nucleoside analog, has been used as a first-line treatment for PACC. While its efficacy is variable, some studies suggest that gemcitabine-based regimens can improve survival outcomes in patients with advanced disease [6].
  • FOLFIRINOX vs. Gemcitabine: A phase II/III trial compared the effectiveness of FOLFIRINOX and gemcitabine in treating PACC. The results showed a significant improvement in overall response rate and progression-free survival with FOLFIRINOX, but further studies are needed to confirm these findings [6].
  • Other chemotherapeutic agents: Sirolimus and vismodegib have been investigated as potential treatments for PACC, although their efficacy is still uncertain. A phase I/II trial evaluating the combination of sirolimus and vismodegib in patients with solid tumors or pancreatic cancer reported promising results [8].

Current Challenges and Future Directions

Despite these treatment options, PACC remains a challenging disease to manage, with limited understanding of its molecular underpinnings. Further research is needed to develop more effective therapies and improve patient outcomes.

  • Molecular characterization: Elucidating the genetic and epigenetic alterations driving PACC will be crucial for identifying novel therapeutic targets.
  • Personalized medicine: Developing treatment strategies tailored to individual patients' characteristics, such as tumor biology and genetic profiles, may help optimize outcomes.

Conclusion

While progress has been made in treating pancreatic acinar cell adenocarcinoma, more research is needed to improve patient outcomes. The current chemotherapeutic regimens, including FOLFIRINOX and gemcitabine-based therapies, offer some promise, but further studies are required to confirm their efficacy and identify new treatment options.

References:

[1] Bizengri: FDA-approved for treating patients with advanced or metastatic NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion. [2] Multicenter retrospective study: Aims to identify the optimal chemotherapeutic regimen for advanced PACC, enrolling 58 patients who received chemotherapy between 1996 and 2013. [3] Symptoms and treatment: Patients diagnosed at a late stage may experience abdominal pain, weight loss, nausea, anorexia, and yellow skin and eyes. Treatments can include chemotherapy, radiotherapy, or other medications.

Note: The information provided is

Differential Diagnosis

The differential diagnosis of pancreatic acinar cell carcinoma (ACC) involves distinguishing it from other types of pancreatic tumors. According to the available information, the main differential diagnoses include:

  • Pancreatic ductal adenocarcinoma (PDAC)
  • Pancreatic neuroendocrine tumor (PNET)

Accurate diagnosis is crucial in these cases, as the treatment and prognosis for each type of tumor can differ significantly.

In terms of morphological features, ACCs are characterized by their distinctive acinar differentiation. However, this feature alone may not be sufficient to rule out other types of pancreatic tumors, such as PDAC or PNET.

Immunostaining is also essential for the definitive diagnosis of ACC. Compared with PDAC, ACCs have distinct immunohistochemical profiles that can help differentiate them from other types of pancreatic tumors [3].

In some cases, the differential diagnosis between ACC and other pancreatic tumor types may be based on a combination of morphological features and immunohistochemical staining [4]. However, it's worth noting that mixed pancreatic acinar cell-ductal adenocarcinomas can also present a challenge in terms of differential diagnosis [5].

Other conditions that may need to be considered in the differential diagnosis of ACC include:

  • Acute pancreatitis
  • Cholangitis
  • Acute cholecystitis
  • Choledochal cysts
  • Chronic pancreatitis
  • Gallstones

It's also worth noting that pancreatic endocrine neoplasms can sometimes be difficult to distinguish from ACC, and may require additional diagnostic testing [7].

References:

[1] by LF Calimano-Ramirez · 2022 · Cited by 29 — Acinar cell carcinoma (ACC) is a rare pancreatic malignancy with distinctive clinical, molecular, and morphological features.

[3] by K Ikezawa · 2024 · Cited by 7 — Immunostaining is essential for the definitive diagnosis of pancreatic acinar cell carcinoma. Compared with pancreatic ductal adenocarcinoma, ...

[4] by S La Rosa · 2015 · Cited by 152 — The differential diagnosis between ACCs and other pancreatic tumor types should be based, first, on morphological features and, then, on immunohistochemical ...

[5] by S Tatli · 2005 · Cited by 192 — The radiologic differential diagnosis of acinar cell carcinoma includes ductal adenocarcinoma, neuroendocrine tumor ... Mixed pancreatic acinar cell-ductal ...

[7] The main differential diagnosis of acinar cell carcinoma is pancreatic endocrine neoplasm. In fact, in some cases, these two tumor types may be nearly indistinguishable.

Additional Differential Diagnoses

Additional Information

oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:5742
core#notation
DOID:5742
oboInOwl#hasDbXref
UMLS_CUI:C0279661
IAO_0000115
A pancreatic adenocarcinoma that has_material_basis_in cells with morphological resemblance to acinar cells and is associated with increased serum lipase.
rdf-schema#label
pancreatic acinar cell adenocarcinoma
oboInOwl#hasExactSynonym
pancreatic acinar cell carcinoma
oboInOwl#inSubset
http://purl.obolibrary.org/obo/doid#NCIthesaurus
rdf-schema#subClassOf
t441677
RO_0004026
http://purl.obolibrary.org/obo/CL_0002064
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class
rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_11814
owl#annotatedSource
t441969

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.